Biotechnology Companies By De
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Debt To Equity
| Debt To Equity | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | TBPH | Theravance Biopharma | 0.01 | 2.67 | 0.01 | ||
| 2 | ATXI | Avenue Therapeutics | (0.24) | 8.55 | (2.05) | ||
| 3 | MNKD | MannKind Corp | (0.20) | 2.03 | (0.40) | ||
| 4 | NVAX | Novavax | (0.01) | 4.72 | (0.05) | ||
| 5 | THRD | Third Harmonic Bio | (0.25) | 6.43 | (1.62) | ||
| 6 | DYAI | Dyadic International | (0.06) | 4.33 | (0.24) | ||
| 7 | ENSC | Ensysce Biosciences | (0.21) | 5.43 | (1.15) | ||
| 8 | HRTX | Heron Therapeuti | 0.16 | 5.55 | 0.88 | ||
| 9 | XCUR | Exicure | 0.01 | 11.80 | 0.07 | ||
| 10 | AXSM | Axsome Therapeutics | 0.15 | 4.11 | 0.63 | ||
| 11 | AGEN | Agenus Inc | (0.12) | 5.49 | (0.68) | ||
| 12 | PROK | ProKidney Corp | (0.13) | 4.65 | (0.59) | ||
| 13 | ALNY | Alnylam Pharmaceuticals | 0.03 | 2.54 | 0.08 | ||
| 14 | AVTX | Avalo Therapeutics | 0.00 | 6.01 | (0.01) | ||
| 15 | THTX | Theratechnologies | (0.04) | 4.27 | (0.15) | ||
| 16 | PBYI | Puma Biotechnology | 0.10 | 4.88 | 0.49 | ||
| 17 | BBIO | BridgeBio Pharma | 0.12 | 3.94 | 0.48 | ||
| 18 | CAPS | Capstone Holding Corp | (0.01) | 8.43 | (0.06) | ||
| 19 | HALO | Halozyme Therapeutics | 0.38 | 1.40 | 0.53 | ||
| 20 | INBX | Inhibrx | 0.00 | 3.46 | (0.01) |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company. High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.